

P&T Motion History Long Acting Opioid

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
buprenorphine buccal film buprenorphine transdermal film fentanyl transdermal film hydrocodone bitartrate hydromorphone levorphanol methadone morphine sulfate morphine sulfate/ naltrexone HCL oxycodone oxycodone HCL/ naloxone HCL oxymorphone tapentadol	<p>After considering the updated evidence of harms, efficacy and special populations for the treatment of non-cancer pain, I move that buprenorphine buccal film, buprenorphine transdermal film, fentanyl transdermal film, hydrocodone bitartrate, hydromorphone, levorphanol, methadone, morphine sulfate, morphine sulfate/ naltrexone HCL, oxycodone, oxycodone HCL/ naloxone HCL, oxymorphone, tapentadol are efficacious when used appropriately. There should be at least one buprenorphine agent and more than one oral preferred drug in the long-acting opioid class preferred in the Washington PDL.</p> <p>Motion: Flynn 2nd: Taylor</p>	June 26, 2024	N/A	No	Passed unanimous

*Not eligible for inclusion on the PDL

Grey = not reviewed, cannot be included in motion

Bold=new this update

7/2/2024